The effect of mandatory generic substitution on the safety of alendronate and patients' adherence

Current Medical Research and Opinion

Volumn 28, Issue 8, 2012, Pages 1347-1355

  Lai, Pauline Siew Mei ^a,b   Chua, Siew Siang ^a   Chong, Yah Huei ^a   Chan, Siew Pheng ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

Author keywords

Alendronate; Generic; Medication adherence; Proprietary; Side effect

Indexed keywords

ALENDRONIC ACID; APO ALENDRONATE; GENERIC DRUG; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOATING; BONE PAIN; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL REFLUX; HEARTBURN; HUMAN; JAW PAIN; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; STOMACH PAIN; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DATA COLLECTION; DRUG SUBSTITUTION; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALAYSIA; MANDATORY PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE;

EID: 84864535663     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.708326     Document Type: Article

References (37)

1. Data on file. Comparative bioavailability of apo-alendronate and Fosamax 40mg tablets under fasting conditions. Apotex Inc Canada, 2005
2. Pharmacy Information System. Data on file: cost of generic alendronate and proprietary alendronate in the University Malaya Medical Centre, 2009 19 June; version 8.6
3. Ministry of Health Malaysia. Generic product list for bioequivalence studies. Kuala Lumpur: National Pharmaceutical Control Bureau, 2011
4. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring, MD 20993: U.S. Department of Health & Human Services; 2012 cited 2012 17 May; 32nd: Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068. htm
5. Ministry of Health Malaysia. Malaysian guidelines for the conduct of bioavailability and bioequivalence studies. In: National Pharmaceutical Control Bureau, editor. Kuala Lumpur, 2000:8-16
6. Food and Drug Administration. Therapeutic Equivalence Evaluations Codes. 2012 updated 2 March 2012; cited 2012 6 March; 32:Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079068.htm Therapeutic%20Equivalence%20Evaluations%20Codes
7. Kanis JA, Reginster JY, Kaufman JM, et al. A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int 2012;23:213-21
8. Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications. Curr Med Res Opin 2008;24:1137-45
9. Epstein S, Geusens P, Fisher JE, et al. Irritation profiles of alendronate formulations: implications for clinical safety and efficacy. J Applied Res 2005;5:253-65
10. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: Office of the Surgeon General, 2004
11. Burge R, Dawson-Hughes B, Solomon DH. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Min Res 2007;22:465-7
12. Cranney A, Guyatt G, Griffith L. IX Summary of meta analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8
13. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis Int 2006;17:1645-52
14. Grima DT, Papaioannou A, Airia P, et al. Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: A retrospective cohort study. BMC Musculoskelet Disord 2010;11:68
15. Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;30:213-21
16. Halkin H, Dushenat M, Silverman B, et al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother 2009;41:29-34
17. Lappe J. Nonadherence to osteoporosis medications: A critical problem. Clin Rev Bone Mineral Metab 2006;4:25-32
18. Siris E, Harris S, Rosen C, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81:1013-22
19. Sebaldt RJ, Shane LG, Pham B, et al. Long-term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphoshonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004;15(s107):Abstract P391SA
20. Tosteston AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;15:209-16
21. Eastell R, Garnero P, Vrijens L, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT study. Calcif Tissue Int 2003;72(408):Abstract P297
22. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998:488-92
23. Dupont WD, Plummer WD. PS: Power and sample size calculation. 2004 updated 12 June; cited 2007 30 June; Available from: http://biostat.mc. vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize
24. Adams CP, Brantner VV. MARKETWATCH: Estimating the cost of new drug development: is it really $802 million? Health Affairs 2006;25:420
25. Xiang XD, Sun X, Briceno G, et al. A combinatorial approach to materials discovery. Science 1995;268:1738-40
26. Bailey WE, Arnold AJ, Lyford TD. Recent Hatch-Waxman reform: balancing innovation, competition and affordability. New York: King & Spalding LLP; 2004 cited 2012 5 March; Available from: http://www.buildingipvalue.com/05-NA/ 107-110.htm
27. Lietzan EK. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. Food Drug Law J 2004;59:287-323
28. Mossinghoff GJ. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food Drug Law J 1998;54:187-94
29. Kibwage IO, Pandjaitan R, Poompanich A, et al. WHO Expert Committee on specifications for pharmaceutical preparations-36th report. Geneva: World Health Organization, 2002
30. Bauer DC, Black DM, Ensrud KE, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Int Med 2000; 160:517-25
31. Fosamax. Product Information (alendronic acid). 1999
32. Amir SK, Chan SP, Abdullah BJ, et al. Clinical Practice Guidelines on Management of Osteoporosis (Malaysian). 2nd edn. Kuala Lumpur, 2006
33. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment-clinical applications. JAMA 2002;288:2880-3
34. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002;288:2868-79
35. Kamatari M, Koto S, Ozawa N, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: Alendronate and risedronate. J Bone Min Metab 2007; 25:302-9
36. Papaioannou A, Ioannidis G, Adachi J, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporosis Int 2003; 14:808-13
37. Bukata SV, Healey JH. Bisphosphonates: A practical guide. Curr Opin Orthop 2004;15:376-7